A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer — MAGNITUDE

Castration-Resistant Prostatic Cancer Clinical Trial

Official title:
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.

Clinical Trial Description

This study will assess efficacy and safety of niraparib in combination with AAP for the treatment of participants with metastatic castration resistant prostate cancer. Niraparib is an orally available, highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. AA is a pro-drug of abiraterone and selectively inhibits the enzyme 17 alpha-hydroxylase/C17,20-lyase (CYP17), which is found in the testes and adrenals, as well as in prostate tissues and tumors. In participants with metastatic prostate cancer, DNA-repair anomalies are identified in approximately 15 percent (%) to 20% of tumors. The study will consist of 5 phases: a prescreening phase for biomarker evaluation only, a screening phase, a treatment phase, a follow up phase, and an extension phase (either open-label extension [OLE] or long-term extension [LTE]). During the prescreening phase participants will be evaluated for homologous recombination repair (HRR) gene alteration status and then will be assigned to one of the 2 cohorts based on their biomarker status. Treatment will be administered daily and is planned to be continuous until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. Efficacy, pharmacokinetics, biomarkers, participants reported outcomes and safety will be assessed. The total duration of study will be approximately 66 months. ;

Study Design

Related Conditions & MeSH terms

Castration-Resistant Prostatic Cancer
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

Clinical Trial Details

NCT number	NCT03748641
Study type	Interventional
Source	Janssen Research & Development, LLC
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	January 25, 2019
Completion date	February 19, 2027

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04116164` - Safety and Targeting of Anti-hk2 Antibody in mCRPC	Early Phase 1
Not yet recruiting	`NCT04126915` - Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES)
Recruiting	`NCT04104607` - the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma	Phase 1
Recruiting	`NCT03016741` - Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer	Phase 4
Completed	`NCT02398526` - Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
Active, not recruiting	`NCT05551117` - A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors	Phase 2
Terminated	`NCT04404140` - A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).	Phase 1
Recruiting	`NCT02998567` - Combination Study of Guadecitabine/ASTX727 and Pembrolizumab	Phase 1
Recruiting	`NCT05293496` - A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors	Phase 1
Available	`NCT06033001` - Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.